Pharmaceutical

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.

Nov 19, 2024 - 06:00
Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.
Read the original article

Tags:

Previous Article

Intellia’s gene editing therapy shows early potential in rare heart condition

Next Article

AbbVie’s Elahere wins European approval for certain ovarian cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Q&A: AMA’s chief health equity officer on ridding medicine of racial essentialism

Q&A: AMA’s chief health equity officer on ridding medic...

Mar 2, 2024

STAT+: House committee hearing kicks off potential doctor pay reforms in Medicare

STAT+: House committee hearing kicks off potential doct...

Oct 20, 2023

Listen: How Long Island became the ‘eugenics capital of the world’

Listen: How Long Island became the ‘eugenics capital of...

Aug 15, 2023